Phathom gets FDA approval for VOQUEZNA to treat heartburn in Non-Erosive GERD

Phathom Pharmaceuticals, Inc.

FDA approved VOQUEZNA (vonoprazan) 10 mg tablets for relief of heartburn associated with Non-Erosive GERD in adults.
This is the third FDA approval for VOQUEZNA; also approved for Erosive GERD and H. pylori eradication.
Approximately 45 million US adults have Non-Erosive GERD; about 15 million treated with prescription medicine annually.
Non-Erosive GERD is the largest GERD category, characterized by reflux symptoms without esophageal erosions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.